The GLP‐1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap

The dermatological community faces an urgent scientific conundrum that demands immediate critical attention: glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are simultaneously emerging as potential therapeutics for inflammatory skin disease and as causative agents of serious cutaneous adverse reactions. This paradox is not merely an academic curiosity—it represents a fundamental gap in our understanding of drug‐skin interactions that could have profound implications for millions of patients worldwide as GLP‐1 RA prescriptions continue to increase substantially.

The therapeutic narrative warrants serious consideration. A 2025 open‐label randomized trial in obese patients with type 2 diabetes and psoriasis demonstrated a 52.4% reduction in Psoriasis Area and Severity Index scores with semaglutide over 12 weeks [1], with benefits also observed in nondiabetic populations with psoriasis and obesity [2]. While these preliminary findings are encouraging, they require confirmation in larger, blinded, controlled trials before clinical recommendations can be made. The proposed mechanism involves anti‐inflammatory effects, including modulation of interleukin (IL)‐17 and tumor necrosis factor‐alpha (TNF‐α) pathways, though whether these effects are independent of metabolic improvements remains incompletely characterized [1]. Yet a critical question remains unanswered: why do some patients appear to experience therapeutic benefit while others develop severe cutaneous toxicity from the same medication class?

The adverse reaction profile is equally striking and deeply troubling. A comprehensive 2025 systematic review identified 34 studies reporting cutaneous adverse effects [3], with documented cases ranging from common injection‐site reactions to rare but serious immune‐mediated conditions including bullous pemphigoid, eosinophilic panniculitis, and leukocytoclastic vasculitis [4]. The phenomenon of accelerated facial aging reflects alterations in subcutaneous adipose tissue architecture that may extend beyond simple volume loss to include effects on tissue homeostasis [5]. The dermatological literature has documented these adverse events with increasing frequency, yet we lack systematic approaches to predict, prevent, or manage them effectively.

The scientific issue at the heart of this debate is our collective failure to identify predictive factors for divergent outcomes. We lack validated biomarkers to distinguish potential therapeutic responders from those at risk for adverse reactions. We have no evidence‐based risk stratification tools despite signals of immune‐mediated pathology in susceptible individuals. We possess minimal mechanistic understanding of why GLP‐1 receptor activation may produce different effects in different patient populations or even within the same individual at different anatomical sites. This knowledge gap is scientifically problematic and clinically concerning, given the rapid growth in GLP‐1 RA prescriptions.

Dermatologists must assume intellectual leadership in addressing this paradox. We cannot allow prescription patterns to be driven without adequate consideration of cutaneous consequences or dermatological expertise. We must demand rigorous post‐marketing pharmacovigilance studies with dermatological endpoints, champion research into predictive factors for adverse reactions, and establish evidence‐based guidelines for patient monitoring and management.

1.

Obtain a medication history including GLP‐1 RAs in all patients presenting with new‐onset inflammatory dermatoses or unexplained cutaneous eruptions. Monitor patients with preexisting inflammatory skin conditions who initiate GLP‐1 RA therapy for both improvement and paradoxical worsening. Evaluate suspected GLP‐1 RA‐induced cutaneous adverse events with appropriate histopathology and consider drug rechallenge only after careful risk–benefit assessment. Report all suspected GLP‐1 RA‐associated cutaneous adverse events to national pharmacovigilance systems to strengthen the evidence base. Counsel patients on both potential dermatological benefits and risks when GLP‐1 RAs are being considered for metabolic indications.

The current approach—reactive management of adverse effects and opportunistic observation of therapeutic benefits—represents a gap in scientific rigor that our specialty should not tolerate. The GLP‐1 RA paradox is not a clinical curiosity to be passively observed; it is an urgent call to action that demands our immediate and sustained intellectual engagement to protect patients and advance dermatological science.

Funding

The authors have nothing to report.

Disclosure

AI was not used in the production of this work.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are openly available 1‐in [MDPI] at [https://www.mdpi.com/2218‐273X/15/1/46] https://doi.org/10.3390/biom15010046. Oxford Academic at https://academic.oup.com/ced/advance‐article‐abstract/doi/10.1093/ced/llag025/8428857?redirectedFrom=PDF, https://doi.org/10.1093/ced/llaf473. In MDPI https://www.mdpi.com/2079‐9721/13/5/127, https://doi.org/10.3390/diseases13050127. In unbound medicine at https://www.unboundmedicine.com/medline/citation/38795152/Rare_cutaneous_adverse_reactions_associated_with_GLP‐1_agonists:_a_review_of_the_published_literature, https://doi.org/10.1007/s00403‐024‐02969‐3. In Oxford Academic at https://academic.oup.com/asj/article/44/11/NP809/7693294, https://doi.org/10.1093/asj/sjae132.